Clinical Trials Data

Selected news for the healthcare topic - Clinical Trials Data, collected since 10/2017. This healthcare topic shares news with Pfizer, COVID-19, Clinical Data and many others.

Please provide a valid email address.

Selected Headlines

Date Headline (link) Source Relevant Snippet
10/7/2021 Life Science Analytics Market Estimated to Observe Significant Growth During – 2027 picayunecurrent.com ... options in the existing study. Life science analytics is used for capitalizing on big data to increase the global collaboration based on accurate clinical research information. The life sciences analytics helps to standardize the clinical trials data and validate its adherence. Advanced analytics aids in early detection of potential risks and also enables to proactively address them. The growth of the life science analytics market can be attributed to the ...
9/30/2021 Global Clinical Trial Management System Market Growth Analysis by biotechnological and pharmaceutical companies tradersherald.com ... Management System Market research is expected to grow significantly during the forecast period. The clinical trial management system is mostly a software system which helps to plan, prepare, and manage a large amount of clinical trials data that is produced by biotechnological and pharmaceutical companies. The system stresses on keeping an up-to-date contact information of applicants and tracking of deadlines for short-term reports. The clinical trial management ...
9/23/2021 Life Science Analytics Market Estimated to Observe Significant Growth During – 2027 picayunecurrent.com ... options in the existing study. Life science analytics is used for capitalizing on big data to increase the global collaboration based on accurate clinical research information. The life sciences analytics helps to standardize the clinical trials data and validate its adherence. Advanced analytics aids in early detection of potential risks and also enables to proactively address them. The growth of the life science analytics market can be attributed to the ...
9/17/2021 Bharat Biotech awaits feedback from WHO for Covaxin EUL portlandnews.net ... obtaining WHO EUL at the earliest," it added.Earlier on Monday, the sources said that the World Health Organisation's (WHO) approval for Covaxin, is expected this week.Bharat Biotech has submitted its Phase 3 clinical trials data that demonstrated 77.8 per cent efficacy to the Subject Expert Committee (SEC) of the Central Drugs Standard Control Organisation (CDSCO).Earlier in June, a pre-submission meeting for WHO Emergency Use Listing Procedure ...
9/16/2021 Close to a decision point, says Dr V K Paul on WHO Emergency Use Listing to Covaxin newkerala.com ... Covaxin have certain imperatives of travel. Most of us, who chose the concurrency, is important in terms of licensure. We are hoping for an early decision." The Bharat Biotech has submitted its Phase 3 clinical trials data that demonstrated 77.8 per cent efficacy to the Subject Expert Committee (SEC) of the Central Drugs Standard Control Organisation (CDSCO). Earlier in June, a pre-submission meeting for EUL was also held that ...
9/15/2021 Covaxin may get WHO approval by month-end, says NITI Aayog weeklyvoice.com ... August, Indian Health Minister Mansukh Mandaviya also met WHO Chief Scientist Dr Soumya Swaminathan and held discussions over the WHO approval of Covaxin. The vaccine’s developer Bharat Biotech has submitted its Phase 3 clinical trials data that demonstrated 77.8 per cent efficacy to the Subject Expert Committee (SEC) of the Central Drugs Standard Control Organisation (CDSCO). The WHO has so far approved Covid-19 vaccines by Pfizer-BioNTech, AstraZeneca ...
9/15/2021 Covaxin may get WHO approval by month-end, says NITI Aayog daijiworld.com ... In August, Indian Health Minister Mansukh Mandaviya also met WHO Chief Scientist Dr Soumya Swaminathan and held discussions over the WHO approval of Covaxin. The vaccine's developer Bharat Biotech has submitted its Phase 3 clinical trials data that demonstrated 77.8 per cent efficacy to the Subject Expert Committee (SEC) of the Central Drugs Standard Control Organisation (CDSCO). The WHO has so far approved Covid-19 vaccines by Pfizer-BioNTech, AstraZeneca ...
9/14/2021 COVID-19: WHO approval for Covaxin expected this week: Sources newkerala.com New Delhi, September 13: The World Health Organisation's (WHO) approval for Bharat Biotech's COVID-19 vaccine, Covaxin, is expected this week, sources said on Monday. Bharat Biotech has submitted its Phase 3 clinical trials data that demonstrated 77.8 per cent efficacy to the Subject Expert Committee (SEC) of the Central Drugs Standard Control Organisation (CDSCO). Bharat Biotech has submitted its Phase 3 clinical trials data that demonstrated 77.8 per cent ...
9/13/2021 WHO nod for COVID-19 vaccine Covaxin expected this week portlandnews.net New Delhi [India], September 13 (ANI): The World Health Organisation's (WHO) approval for Bharat Biotech's COVID-19 vaccine, Covaxin, is expected this week, sources said on Monday.Bharat Biotech has submitted its Phase 3 clinical trials data that demonstrated 77.8 per cent efficacy to the Subject Expert Committee (SEC) of the Central Drugs Standard Control Organisation (CDSCO).Earlier in June, a pre-submission meeting for WHO Emergency Use Listing Procedure ...
9/13/2021 WHO nod for COVID-19 vaccine Covaxin expected this week bignewsnetwork.com New Delhi [India], September 13 (ANI): The World Health Organisation's (WHO) approval for Bharat Biotech's COVID-19 vaccine, Covaxin, is expected this week, sources said on Monday. Bharat Biotech has submitted its Phase 3 clinical trials data that demonstrated 77.8 per cent efficacy to the Subject Expert Committee (SEC) of the Central Drugs Standard Control Organisation (CDSCO). Earlier in June, a pre-submission meeting for WHO Emergency Use Listing Procedure ...
9/13/2021 COVID-19: WHO approval for Covaxin expected this week: Sources Yahoo News Representative image New Delhi [India], September 13 (ANI): The World Health Organisation's (WHO) approval for Bharat Biotech's COVID-19 vaccine, Covaxin, is expected this week, sources said on Monday.Bharat Biotech has submitted its Phase 3 clinical trials data that demonstrated 77.8 per cent efficacy to the Subject Expert Committee (SEC) of the Central Drugs Standard Control Organisation (CDSCO).Earlier in June, a pre-submission meeting for WHO Emergency Use ...
9/13/2021 WHO nod for COVID-19 vaccine Covaxin expected this week - NewsBreak newsbreak.com New Delhi [India], September 13 (ANI): The World Health Organisation's (WHO) approval for Bharat Biotech's COVID-19 vaccine, Covaxin, is expected this week, sources said on Monday. Bharat Biotech has submitted its Phase 3 clinical trials data that demonstrated 77.8 per cent efficacy to the Subject Expert Committee (SEC) of the ...
9/8/2021 -E-book- The Wills Eye Manual: Office and Emergency Room Diagnosis and Treatment of Eye Disease Epub slideshare.net ... to bring this pocket-sized reference thoroughly up to date – including extensive multimedia content – while retaining the features that have made it so useful in daily practice.New to this edition:Recent major clinical trials data Expertly produced videos depicting a wide range of common procedures with step-by-step narration, carefully selected to complement key techniquesChanging trends in trauma, oculoplastics, cornea, pediatrics, neuro-ophthalmology, uveitis, and moreOutstanding features you ...
9/8/2021 DCGI Approves Advanced Trials for Biological E. Limited's COVID- 19 Vaccine delhipostnews.com ... Biological E. Limited for conducting Phase III comparator safety and immunogenicity trial in adults of its CORBEVAX™ vaccine against COVID-19 after Subject Expert Committee’s (SEC) review of Phase I and II clinical trials data . var betteradsscreenwidth = document.body.clientWidth;betteradsel = document.getElementById('bsac-16293-1321273605'); if (betteradsel.getBoundingClientRect().width) ( betteradselwidthraw = betteradselwidth = betteradsel.getBoundingClientRect().width; ) else ( betteradselwidthraw = betteradsel_width = betterads ...
9/7/2021 COVID-19: WHO approval for Covaxin expected this week, say sources newindianexpress.com COVID-19: WHO approval for Covaxin expected this week, say sources Bharat Biotech has submitted its Phase 3 clinical trials data that demonstrated 77.8 per cent efficacy to the Subject Expert Committee of the Central Drugs Standard Control Organisation. NEW DELHI: The World Health Organisation's (WHO) approval for Bharat Biotech's COVID-19 vaccine, Covaxin, is expected this week, sources said on Monday. Bharat Biotech has submitted its Phase 3 clinical ...
9/7/2021 Point-of-care detection and differentiation of anticoagulant therapy - development of thromboelastometry-guided decision-making support algorithms biomedcentral.com ... DXaIs), the direct thrombin inhibitor (DTI) dabigatran, as well as vitamin K antagonists (VKA) and dilutional coagulopathy (DIL) with high accuracy. Methods Following ethics committee approval (No 17–525-4), and registration by the German clinical trials data base we conducted a prospective observational trial including 50 anticoagulated patients (n = 10 of either DOAC/VKA) and 20 healthy volunteers. Blood was drawn independent of last intake of coagulation inhibitor. Healthy volunteers served ...
9/3/2021 Biological E's Corbevax gets DGCI approval for two clinical trials newsvibesofindia.com ... and Technology said today.Biological E, the Hyderabad-based pharmaceutical company received approval for Phase III Comparator Safety & Immunogenicity trial in adults after Subject Expert Committee’s (SEC) review of Phase I and II clinical trials data , the Ministry said in a statement.Additionally, it had also received approval on September 1 to initiate the Phase II/III study to evaluate Safety, Reactogenicity, Tolerability and Immunogenicity of CORBEVAX™ vaccine ...
9/3/2021 Biological E gets DCGI's nod for phase 2/3 clinical trial of Corbevax on children, adults jagran.com The approval of DCGI for conducting phase III comparator safety and immunogenicity trial in adults came after the Subject Expert Committee's (SEC) review of Phase I and II clinical trials data . Updated: Fri, 03 Sep 2021 09:35 PM IST subs File Image for RepresentationNew Delhi Jagran News Desk: With an aim to inoculate the complete population by the end of this year, the Drugs Controller General of India (DCGI ...
9/3/2021 Department of Biotechnology Mission COVID Suraksha Supported Biological E Limited Novel Covid-19 Vaccine candidate – CORBEVAX receives DCGI approval for Two Clinical Trials orissadiary.com ... BIRAC. Biological E. has received Drugs Controller General of India (DCGI) approval for conducting Phase III Comparator Safety & Immunogenicity trial in adults after Subject Expert Committee’s (SEC) review of Phase I and II clinical trials data . Additionally, Biological E. also received approval on 01.09.2021 to initiate the Phase II/III Study to evaluate Safety, Reactogenicity, Tolerability and Immunogenicity of CORBEVAX™ vaccine in Children and Adolescents. The candidate is ...
9/3/2021 DGCI Approves Clinical Trials Of Biological E Covid-19 Vaccine CORBEVAX On Adults & Children ommcomnews.com ... BIRAC. Biological E. has received Drugs Controller General of India (DCGI) approval for conducting Phase III Comparator Safety & Immunogenicity trial in adults after Subject Expert Committee’s (SEC) review of Phase I and II clinical trials data . Additionally, Biological E. also received approval on September 1, to initiate the Phase II/III Study to evaluate Safety, Reactogenicity, Tolerability and Immunogenicity of CORBEVAX™ vaccine in Children and Adolescents. The candidate ...